When was Alvine Pharma founded?

Alvine Pharma was founded in 2005 and raised its 1st funding round 3 years after it was founded.

Where is Alvine Pharma located?

Alvine Pharma is headquartered in San Carlos, United States.

Is Alvine Pharma a funded company?

Alvine Pharma is a funded company, having raised a total of $135M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 2008.

When was the latest funding round of Alvine Pharma?

Alvine Pharma's latest funding was a $***** Series B round on May 14, 2013, with participation from 1 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.02B in funding in 2026 to date.

Where does Alvine Pharma rank among its competitors?

Alvine Pharma ranks 124th amongst 421 active competitors, of which 140 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Alvine Pharma?

Alvine Pharma's top competitors include BeiGene, Biogen and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Alvine Pharma - 2026 Company Profile, Funding & Competitors

Company Details

Online platform offering slot games with QRIS payment and exclusive bonuses. This platform is a destination for online gaming, specializing in slot games. It provides a seamless experience with QRIS payment integration, enabling instant deposits via mobile banking and e-wallets. The platform offers a variety of slot games, including popular titles and new releases, with features like scatter bonuses and VIP membership perks. It focuses on user experience, offering customer support through live chat and multiple channels. The platform promotes responsible gaming and provides a secure environment for players to enjoy their favorite slot games. It also features login and registration options, along with promotional offers and bonus programs.

Key Metrics

Founded Year

2005

Location

San Carlos, United States

Stage

Acquired

Total Funding

$135M in 6 rounds

Latest Funding Round

Series B, May 14, 2013, $*****

Investors

Panorama Capital & 8 more

Ranked

124^th among 421 active competitors

Similar Companies

BeiGene & 491 more

Exit Details

Acquired by Immunogenx (Mar 15, 2016)

View Alvine Pharma's full profile

Alvine Pharma got acquired by Immunogenx on Mar 15, 2016.

Click here to take a look at Alvine Pharma's acquisition in detail

Alvine Pharma has raised a total funding of $135M over 6 rounds. Its first funding round was on May 2008. Its latest funding round was a Series B round on May 14, 2013 for $*****. 1 investor participated in its latest round. Alvine Pharma has 9 institutional investors.

Here is the list of recent funding rounds of Alvine Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 14, 2013	9151144	Series B	4999431	1555480	7542574	1724817
Jan 02, 2013	9289564	Series A	5966838	9580854	3317157	6860001
Oct 12, 2011	3112006	Convertible Debt	7695297	5441925	3548270	5426877

Access funding benchmarks and valuations. Sign up today!

View details of Alvine Pharma's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alvine Pharma include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Alvine Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
124th	Alvine Pharma 2005, San Carlos (United States), Acquired	Online platform offering slot games with QRIS payment and exclusive bonuses	$135M	AbbVie, Sofinnova Investments & 7 others	44/100